Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 155

Results For "old"

2418 News Found

NHA organises workshop to accelerate adoption of ABDM
Policy | November 01, 2022

NHA organises workshop to accelerate adoption of ABDM

The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage


Prasad Raghava Menon appointed Additional Director of Neuland Laboratories
People | November 01, 2022

Prasad Raghava Menon appointed Additional Director of Neuland Laboratories

Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry


Aptar Pharma completes Phase I global injectables expansion program
News | November 01, 2022

Aptar Pharma completes Phase I global injectables expansion program

The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.


Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.


21.4 lakh TB cases notified in India in 2021
Policy | October 30, 2022

21.4 lakh TB cases notified in India in 2021

Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today


Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
News | October 27, 2022

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr


Robert M. Davis is the new Chairman of Merck
People | October 27, 2022

Robert M. Davis is the new Chairman of Merck

Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.


Novartis maintains growth momentum; Confirms FY’22 Group guidance
News | October 26, 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.


AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
Clinical Trials | October 26, 2022

AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.